[ Grossesse extra-utérine rompue après un traitement médical par Méthotrexate (MTX) : A propos de trois observations avec revue de la littérature ]
Volume 19, Issue 2, December 2015, Pages 223–228
Youssef Benabdejlil1, Ghizlane Salek2, Ihssane Hakimi3, Khalid Guelzim4, Jaouad Kouach5, Driss Moussaoui6, and Mohammed Dehayni7
1 Department of Gynecology-Obstetric, Military Training Hospital Med V, Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco
2 Service de gynécologie-obstétrique, Hôpital Militaire d'instruction Mohamed V, Rabat, Morocco
3 Service de Gynécologie Obstétrique, Hôpital Militaire d'Instruction Mohamed V, Rabat, Morocco
4 Faculté de Médecine et de Pharmacie, Université Mohamed V, Rabat, Morocco
5 Faculté de Médecine et de Pharmacie, Université Mohamed V, Rabat, Morocco
6 Department of Gynecology-Obstetric, Military Training Hospital Med V, Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco
7 Department of Gynecology-Obstetric, Military Training Hospital Med V, Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco
Original language: French
Copyright © 2015 ISSR Journals. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Medical treatment of ectopic pregnancy (EP) is based on the administration of methotrexate (MTX). It concerns ectopic pregnancy with β-hCG <10000 without cardiac activity and applies to women informed, without history of ectopic pregnancy and who understand the predictive signs of break. These women should always be monitored until β-hCG negativity. The risk of tubal break persists throughout the treatment with MTX. The authors report three cases of ectopic pregnancy treated medically and whose evolution has been marked by a break. They talk through these cases about the indications and limitations of medical treatment and the risks of tubal break under medical treatment.
Author Keywords: Ectopic, pregnancy, Methotrexate, tubal, break.
Volume 19, Issue 2, December 2015, Pages 223–228
Youssef Benabdejlil1, Ghizlane Salek2, Ihssane Hakimi3, Khalid Guelzim4, Jaouad Kouach5, Driss Moussaoui6, and Mohammed Dehayni7
1 Department of Gynecology-Obstetric, Military Training Hospital Med V, Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco
2 Service de gynécologie-obstétrique, Hôpital Militaire d'instruction Mohamed V, Rabat, Morocco
3 Service de Gynécologie Obstétrique, Hôpital Militaire d'Instruction Mohamed V, Rabat, Morocco
4 Faculté de Médecine et de Pharmacie, Université Mohamed V, Rabat, Morocco
5 Faculté de Médecine et de Pharmacie, Université Mohamed V, Rabat, Morocco
6 Department of Gynecology-Obstetric, Military Training Hospital Med V, Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco
7 Department of Gynecology-Obstetric, Military Training Hospital Med V, Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco
Original language: French
Copyright © 2015 ISSR Journals. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Medical treatment of ectopic pregnancy (EP) is based on the administration of methotrexate (MTX). It concerns ectopic pregnancy with β-hCG <10000 without cardiac activity and applies to women informed, without history of ectopic pregnancy and who understand the predictive signs of break. These women should always be monitored until β-hCG negativity. The risk of tubal break persists throughout the treatment with MTX. The authors report three cases of ectopic pregnancy treated medically and whose evolution has been marked by a break. They talk through these cases about the indications and limitations of medical treatment and the risks of tubal break under medical treatment.
Author Keywords: Ectopic, pregnancy, Methotrexate, tubal, break.
Abstract: (french)
Le traitement médical de la grossesse extra-utérine (GEU) repose sur l'administration du Méthotrexate (MTX). Il concerne les GEU peu évolutives (β-hCG< 10000 sans activité cardiaque) et s'applique aux femmes informées, compliantes, sans antécédent de GEU et qui comprennent les signes prédictifs de rupture. Celles-ci devront impérativement être surveillées jusqu'à négativation des β-hCG. Le risque de rupture tubaire persistant pendant toute la durée du traitement par MTX. Les auteurs rapportent trois cas de GEU traités médicalement et dont l'évolution a été marquée par une rupture. Ils discutent à travers ces trois observations les indications et les limites du traitement médical ainsi que les risques de rupture tubaire sous traitement médical.
Author Keywords: Grossesse, ectopique, Méthotrexate, rupture, trompe.
How to Cite this Article
Youssef Benabdejlil, Ghizlane Salek, Ihssane Hakimi, Khalid Guelzim, Jaouad Kouach, Driss Moussaoui, and Mohammed Dehayni, “Ectopic pregnancy broken after medical treatment by Methotrexate (MTX) : Report of three cases with review of the literature,” International Journal of Innovation and Scientific Research, vol. 19, no. 2, pp. 223–228, December 2015.
